Classification of B-cell non-Hodgkin lymphomas (NHL)

Identity

Note
B-cell NHL include a number of clinicopathologic subsets of lymphoid neoplasms having heterogeneous features. This situation is reflected by variations in the classification systems that were proposed over the last decade. Cytogenetic findings were recognized to help defining a rationale biologic ground for the nosologic classification of lymphomas. An outlook of the salient cytogenetic entities in this spectrum of disorders is presented herein; a complete illustration of the cytogenetic profile of each disease is provided in specific cards. Unless otherwise specified the WHO classification system will be used.

Legend for immunophenotypes (below): +: positive in >90% of the cases; +/-: positive in more than 50% of the cases; -/+: positive in less than 50% of cases; -: positive in <10% of the cases; pan-B markers include CD19; CD20; CD79a; R = rearranged; slg: surface immunoglobulins; cyIg: cytoplasmic Ig; IgV genes: genes encoding for the variable portion of the Ig.

Clinics and Pathology

Disease
Small lymphocytic lymphoma (SLL)

Phenotype / cell stem origin
Histologic subset and Immunophenotype: Pan-B+; CD5+; CD23+; CD10-; slgM+ faint.

Putative cell of origin: CD5+ virgin B-cell with germline IgV genes (as was recently demonstrated to be the case with chronic lymphocytic leukemia, the leukemic counterpart of SLL, it is likely that part of the cases may derive from post-germinal centre quiescent B-cells that harbour hypermutated IgV genes)

Clinics
Indolent disease; leukemic involvement by lymphoid cells, including prolymphocytes and/or paraimmunoblasts Splenomegaly

Cytogenetics
del(6)(q21-23) (20-30% of the cases)

Disease
Lymphoplasmacytic lymphoma

Phenotype / cell stem origin
Histologic subset and Immunophenotype: Pan-B+; CD5-; CD10-; cyIgM+

Putative cell of origin: Peripheral B-lymphocyte transforming into plasma cell with mutated IgV genes and ongoing mutations

Clinics
Indolent low-grade disease, with possible clinical and/or histologic...
Cytogenetics  \textit{t(9;14)(p13;q32) PAX5/IgH} (50\% of cases)

Disease  \textbf{Follicle centre cell lymphoma}
Phenotype / cell stem origin  Histologic subset and Immunophenotype: Pan-B+; CD10+-/-; CD5-; slg+
Putative cell of origin: Centrocyes / centroblasts of germinal centre origin with somatic hypermutation of the IgV genes and ongoing mutations (antigen driven stimulation)
Clinics  Indolent. Advanced stages predominate. Conflicting data as to the prognostic significance of the \textit{t(14;18)/BCL2}
Cytogenetics  \textit{t(14;18)(q32;q21) / BCL2} Rearr (70-80\% of cases)

Disease  \textbf{Diffuse large cell lymphoma}
Phenotype / cell stem origin  Histologic subset and Immunophenotype: CD19+; CD22+; CD10-/+; SIg+
Putative cell of origin: Large transformed B-cells harbouring somatic hypermutation of the Ig genes (ongoing mutations in some cases)
Clinics  Usually aggressive
Immunoblastic lymphoma (Kiel classification) do worse than centroblastic lymphomas
No convincing demonstration that any "primary" cytogenetic / molecular defect has prognostic significance; complex karyotype confers a shorter survival
Cytogenetics  \textit{t(14;18)} and \textit{p53} mutations (20\% of the cases)
\textit{t(3;V)(q27;V)/BCL6} Rearr (6-30\% of cases (% variations depending on detection methods: molecular genetics and FISH more sensitive that conventional cytogenetics))
or variants \textit{c-MYC} Rearr (7-10\% of cases)

Disease  \textbf{Burkitt's lymphoma}
Phenotype / cell stem origin  Histologic subset and Immunophenotype: Pan-B+; TdT-; CD10+; CD5-; slgM+
Putative cell of origin: Peripheral B-cells that have encountered the antigen and harbours somatic hypermutation of the Ig genes
Clinics  Extremely aggressive disease
Specific treatment mandatory
Cytogenetics  \textit{t(8;14)(q24;q32) ID1050> or variants / R earr (80\% of the cases) GENES}

Disease  \textbf{Burkitt-like lymphoma}
Phenotype / cell stem origin  Histologic subset and Immunophenotype: Pan-B+; TdT-; CD10-/+; CD5-; slg+
Putative cell of origin: Peripheral B-cells that have encountered the
antigen

**Clinics**

Aggressive disease
Cases with dual 8;14 and 14;18 translocations have a worse outcome (data requiring confirmation -1 study only)

**Cytogenetics**

- t(8;14) or variants (25% of cases)
- t(8;14)+ t(14;18) (30% of cases)

**Disease**

**Mantle cell lymphoma**

**Phenotype / cell stem origin**
Histologic subset and Immunophenotype: Pan-B +; CD5+; CD23-; CD10-/+; sIgM+ bright
Putative cell of origin: CD5+ B-cells of the follicle mantle having germline IgV gene sequences

**Clinics**

Advanced stages predominate
Response to chemotherapy often unsatisfactory
Short survival
Complex karyotype carries an unfavourable prognostic significance

**Cytogenetics**

- t(11;14)(q13;q32) / BCL1 Rearr (50-90%) (molecular genetic methods have limited application due to variability of breakpoints; FISH is the most sensitive technique)

**Disease**

**Marginal zone B-cell lymphoma** (MZBCL)

**Phenotype / cell stem origin**
Histologic subset and Immunophenotype: pan-B+; CD5-/+; CD10-; CD23-; CD11c+/-; cylg + (40% of the cells), slgM+ bright; slgD-
Putative cell of origin: Marginal zone lymphocytes harbouring hypermutated IgV genes

**Cytogenetics**

- t(11;18)(q21;q21) ID: 2022> / P12 / MLT fusion (30-50% of the low-grade MALT): Extra-nodal low-grade MALT lymphoma; indolent disease
- t(1;14)(p21;q32): Extra-nodal MALT lymphoma
del(7)(q22-31) (40% of the cases): Splenic MZBCL
+3q (30-70% of the cases): Nodal, extra-nodal and splenic MZBCL

**Bibliography**

- t(9,14)(p13;q32) denotes a subset of low-grade non Hodgkin s lymphoma with plasmacytoid differentiation.
  Offitt KA, Parsa NZ, Filippa D, Jhanwar SC, Chaganti RSK.

- Prognostic value of chromosomal abnormalities in follicular lymphoma.

- Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large cell lymphoma.

Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobiological features.
in multiple tumor types.

**Contributor(s)**

*Written*

02-2000  Antonio Cuneo

**Citation**

*This paper should be referenced as such:*


URL: http://AtlasGeneticsOncology.org/Anomalies/BNHLClassifID2067.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology